Cover Image: September 2010 Scientific American Magazine See Inside

Fat Attack: Will Three New Antiobesity Drugs Beat a Checkered Safety History?

The U.S. Food and Drug Administration prepares to weigh the safety and efficacy of new flab fighters















Share on Tumblr

fat-chid-exercisiing-hula-hoop-on-arm

OBESITY is best tackled with good eating and exercise habits beginning when one is young. Radical solutions such as gastric bypass surgery could be replaced by new antiobesity drugs, if deemed safe enough. Image: SANDY NICHOLSON/REDUX PICTURES

Finding safe and effective weight-loss medications has long been a goal for drugmakers and physicians alike—roughly one third of American adults meet the clinical criteria for obesity, according to the Centers for Disease Control and Prevention. This year the U.S. Food and Drug Administration has been reviewing three new antiobesity drugs for government approval. Given the field’s checkered past, however, major questions remain about the risks of pills that pare away the pounds.

Although drugs that seem promising early on sometimes prove ineffective or downright dangerous after they hit the market, the obesity field has seen more than its share of failures. In the 1960s amphetamines were touted as the answer to weight loss until they proved habit-forming. The mid-1990s witnessed the disaster with fen-phen (fenfluramine and phentermine), which caused heart valve disease. Then just a few years ago the FDA denied approval for a new weight-loss drug after it was linked to suicidal behavior.

To date, only two drugs are FDA-approved for long-term treatment of obesity, and they are not without concern. Earlier this year the European Union banned one of the compounds, sibutramine, or Meridia, after new reports of heart attack and stroke. The other drug, orlistat, now sold over the counter as Alli, causes gastrointestinal distress and has been associated with liver damage in some patients.

Nevertheless, researchers think drugs are the way to go and hope medications will one day replace costly and potentially dangerous surgeries such as gastric bypass. The situation is not unlike that for hypertension before the middle of the 20th century: until the advent of beta blockers in the 1960s, physicians removed sections of peripheral nerves to control high blood pressure. Today physicians treat hypertension almost exclusively with medication. Developing drugs for a chronic condition, whether it is obesity or hypertension, is challenging, though. “Most chronic diseases have lots of redundant mechanisms, so it is unusual to find a ‘magic bullet,’” explains Frank Greenway, chief of the outpatient clinic at the Pennington Biomedical Research Center in Baton Rouge, La.

Obesity has a neuropsychiatric component, which makes it especially troublesome to treat. Each of the three new drugs facing FDA review targets the brain differently. One drug, called Contrave, takes aim at the brain’s reward pathway, whereas the other two compounds affect brain areas that are involved with appetite. All three drugs appear to induce long-term weight loss. The concern is that like antiobesity drugs before them, which also targeted the brain, they could cause unwanted effects on the central and peripheral nervous systems.

Lorcaserin, one of the three new drugs, affects serotonin, which involves multiple brain processes besides appetite, including emotion and cardiovascular regulation. The company behind lorcaserin, San Diego–based Arena Pharmaceuticals, has gone to great lengths to show that the chemical does not cause the serotonin-related heart valve problems associated with fen-phen. Yet the drug could still lead to depression or increased cardiac risk factors, such as high blood pressure, especially if patients combine it with other drugs in an attempt to hasten weight loss.

The other two drugs, Contrave and Qnexa, could also cause unwanted neurological side effects. Bupropion, an ingredient in Contrave, has been linked to anxiety; topiramate, Qnexa’s main ingredient, has been associated with memory problems. The companies behind Contrave and Qnexa—Orexigen in La Jolla, Calif., and Vivus in Mountain View, Calif., respectively—maintain that by combining the drugs with other agents, they have brought the doses below levels that would trigger adverse reactions. “Finding the right dosage is key,” says Barbara Trou­pin, senior director of medical affairs at Vivus.



5 Comments

Add Comment
View
  1. 1. drkathyday@gmail.com 11:15 PM 9/6/10

    None of these new medications appear to have the substantial, rapid weight loss that surgery provides. Losses of 5%-10% are usual, over a period of months. Tests to see whether weight loss is sustained are not yet available. So for a 6 foot man weighing 275, that is, about 100 pounds over his ideal weight, these medications could be expected to help him lose about 12 to 25 pounds over a period of several months. While this is beneficial, it is not the major impact of bariatric surgery.

    Reply | Report Abuse | Link to this
  2. 2. devinci 10:33 AM 9/14/10

    This particular condition has the unique qualifier that it can only become epidemic in a culture of excess. Which suggests that the root of the problem for the majority, is one of self-control and moderation. Spending money on bandages to the problem is not a logical solution.

    Reply | Report Abuse | Link to this
  3. 3. mikecimerian 03:52 AM 9/15/10

    @devinci I agree.

    The whole concept of diet exists in denial of our biological heritage. The body interprets any sudden shortage as a signal to metabolize fat. It is a survival trait.

    Metabolism has to remain "motivated" which means that we have to tolerate certain thresholds of hunger.

    Who knows we may even become light headed once in a while, it isn't a bad experience.

    Reply | Report Abuse | Link to this
  4. 4. galaxy_man 02:23 PM 9/15/10

    Anti-obesity drugs will never work because they always address the symptoms, never the problem.

    Reply | Report Abuse | Link to this
  5. 5. joenn 10:37 PM 9/17/10

    This may sound like a dumb question but what is wrong with just eating right? It doesn't take a Mensa member mentality to figure out that the reason that most fat people are fat is because of their really bad eating habits. There is no way that the body can work right if it doesn't have the right nutrients to do what it does. It is not surprising that people are sick, fat, and hungry all the time. The bad food they are eating is making them sick, fat, and hungry. Drugs are not the answer either. They are part of the problem. They damage the body so it handicaped even more. The real solution is to eat the food that humans were intended to eat. Fruits, vegetables, and grains processed as little as possible. The local fast food places have none of the above.

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

More »

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital

Latest from SA Blog Network

  SA Digital

Science Jobs of the Week

Email this Article

Fat Attack: Will Three New Antiobesity Drugs Beat a Checkered Safety History?: Scientific American Magazine

X
Scientific American Magazine

Subscribe Today

Save 66% off the cover price and get a free gift!

Learn More >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X